中医药治疗原发性非小细胞肺癌疗效的Meta分析  

Meta Analysis on Primary Non- small Cell Lung Carcinoma (NSCL) Treated by TCM in China

作　　者：陈志峰[1] 李成柱[2] 刘少翔[1] 侯浚[1] 王济民[2] 

机构地区：[1]河北省肿瘤研究所,石家庄市健康路5号050011 [2]河北省医学科学院附属医院

出　　处：《中医杂志》1999年第5期287-289,共3页Journal of Traditional Chinese Medicine

摘　　要：应用Meta分析方法(MA)的随机效应模型,对国内7年来单纯采用中医药治疗原发性非小细胞肺癌(NSCL),并以化疗作对照的研究文献进行定量合并分析。MA结果显示,中医药组稳定率OR=2.10,95％CI(0.70～3.08),资料齐性检验Q=24.24,V=12,P>0.01;化疗组有效率OR=1.48,95％CI(1.03～2.24),Q=2.89,V=8,P>0.05。统计7篇文献中位生存期,中医药组平均335.4天,化疗组231.8天,显著性检验P=0.1489。MA结果表明,中医药治疗NSCL疗效特点为稳定率高,有效率低,但中医药组远期生存显示了一定的优势。Chen Zhifeng, Li Chengzhu, Liu Shaoxiang et al. By applying random - effect model of meta analysis (MA), quantitative analysis was also made on literatures of non - small cell lung - cancer treated with TCM alone in the past 7 years, with that treated by chemotherapy as control. MA results showed that the stability rate of TCM group was OR = 2. 10, 95% CI (0. 70-3. 08), complete data exam Q = 24. 24, V = 12 F>0. 01. In the themotherapeutic group. OR = 1.48, 95% CI (1.03-2. 24), Q = 2. 89, V = 8, P> 0.05. Statistics from 7 papers revealed the mean survival rate of TCM group was 335. 4 days, that of chemotherapeutic group 231. 8, test of significance P = 0. 1489. MA results showed that the features of TCM treatment on NSCL were: high stability, low effectiveness, however, with certain dominance. Authors' address: Institute of Oncology, Shijiazhuang, Hebei 050011

关 键 词：肺肿瘤 中医药疗法 META分析 非小细胞肺癌 

分 类 号：R273.42[医药卫生—中西医结合]